News
Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.
Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback